Filgrastim biosimilar - Mycenax BiotechAlternative Names: GranNEX
Latest Information Update: 04 Aug 2015
$50 / €47 *
At a glance
- Originator Mycenax Biotech
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
- Mechanism of Action Granulocyte colony stimulating factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Neutropenia
Highest Development Phases
- Preregistration Neutropenia
Most Recent Events
- 04 Jun 2015 Filgrastim biosimilar - Mycenax Biotech is available for licensing in World as of 04 Jun 2015.
- 08 Aug 2013 Biomarkers information updated